- Home
- BWIN vs ARDX Comparison
BWIN vs ARDX Comparison
Compare BWIN & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BWIN | ARDX |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BWIN | ARDX |
|---|---|---|
| Price | $26.25 | $6.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $36.17 | $10.65 |
| AVG Volume (30 Days) | 1.1M | ★ 3.7M |
| Earning Date | 02-24-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,487,497,000.00 | $398,234,000.00 |
| Revenue This Year | $10.94 | $22.77 |
| Revenue Next Year | $24.72 | $28.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 10.69 | ★ 58.12 |
| 52 Week Low | $21.26 | $3.21 |
| 52 Week High | $47.15 | $6.78 |
Technical Indicators
Market Signals| Indicator | BWIN | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 58.36 | 67.43 |
| Support Level | $23.35 | $5.53 |
| Resistance Level | $25.40 | $6.40 |
| Average True Range (ATR) | 1.30 | 0.35 |
| MACD | 0.24 | 0.06 |
| Stochastic Oscillator | 96.08 | 98.98 |
Price Performance
Historical ComparisonAbout BWIN The Baldwin Insurance Group Inc.
The Baldwin Insurance Group Inc is a United States-based insurance distribution firm. Its products include Business Insurance, Benefits Consulting, Reinsurance, Specialty MGA, Embedded Insurance., Personal insurance, etc.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.